MASM7 |
Catalog No.GC65890
One-Click Copy Product Info
|
MASM7 is a mitofusin activator that concentration-dependently increases Mito AR (Mitochondrial Aspect Ratio; EC50=75nM) in MEF cells.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 920868-45-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MASM7 is a mitofusin activator that concentration-dependently increases Mito AR (Mitochondrial Aspect Ratio; EC50=75nM) in MEF cells. MASM7 directly binds to the HR2 domain of MFN2 (Kd=1.1μM) to activate MFN2 or MFN and induce mitochondrial fusion. MASM7 can be used in research related to mitochondrial function, cellular energy metabolism, and inflammation regulation (such as dental pulp repair)[1-4].
In vitro, MASM7 (1μM) was used to treat endothelial progenitor cells cultured with conditioned medium from sodium caffeine benzoate-incubated RAW264.7 cells for 24 hours. MASM7 enhanced the angiogenic capacity of endothelial progenitor cells, reversed mitochondrial swelling, reduced reactive oxygen species production, increased mitochondrial membrane potential levels, elevated OPA1, p-AKT, and p-GSK3β protein expression, and decreased DRP1 protein expression[5]. MASM7 (1μM) was used to treat human bone marrow mesenchymal stem cells transfected with a short hairpin-FoxO1 plasmid and induced with BMP-2 (10ng/ml) for 7 days. MASM7 significantly reduced cytoplasmic mitochondrial DNA levels, decreased mitochondrial membrane potential levels, increased adenosine triphosphate content, enhanced mitochondrial autophagy, promoted cell proliferation and migration, reduced apoptosis, and increased extracellular matrix calcium deposition[6].
In vivo, MASM7 (10μg in 10μl; once daily) was administered via intrathecal injection to rats with a skin/muscle incision and retraction model for seven consecutive days. MASM7 alleviated skin/muscle incision and retraction-induced mechanical allodynia, improved mitochondrial function, reduced reactive oxygen species accumulation, and mitigated pyroptosis of gamma-aminobutyric acid-ergic neurons in the spinal cord[7]. MASM7 hydrogel (20mM/1ml; 2μl/tooth; single treatment) was topically applied to the teeth of a rat model of pulpitis, followed by ultraviolet light (405nm, 50mW/cm²) irradiation for 30 seconds. The MASM7 hydrogel promoted the repair of dental pulp tissue under inflammatory conditions by regulating macrophage polarization and scavenging reactive oxygen species[8].
References:
[1] Zacharioudakis E, Agianian B, Kumar Mv V, et al. Modulating mitofusins to control mitochondrial function and signaling. Nat Commun. 2022 Jul 7;13(1):3775.
[2] Yu T, Wei J, Tian L, et al. Caffeine Sodium Benzoate Promotes Endothelial Dysfunction of Human Umbilical Vein Endothelial Cells by Promoting M1 Macrophage Polarization. Mol Biotechnol. 2026 Feb;68(2):572-586.
[3] Guo J, Chi W, Zhang K, et al. Hippocampal HDAC7 induces perioperative neurocognitive disorders via an NF-κB-MFN2-ACSL4 ferroptosis pathway. Cell Signal. 2026 Aug;144:112531.
[4] Wei FL, Wang TF, Wang CL, et al. Cytoplasmic Escape of Mitochondrial DNA Mediated by Mfn2 Downregulation Promotes Microglial Activation via cGas-Sting Axis in Spinal Cord Injury. Adv Sci (Weinh). 2024 Jan;11(4):e2305442.
[5] Yu T, Yuan Y, Suo F, et al. Caffeine Sodium Benzoate-Induced Macrophage M1 Polarization Promotes Endothelial Progenitor Cell Dysfunction by Inducing Mitochondrial Dysfunction Via Targeting let-7a-5p/OPA1 Axis. Appl Biochem Biotechnol. 2026 Apr;198(4):2918-2940.
[6] Feng W, Chen N, Chen K, et al. Forkhead box O-1 regulates the biological behavior of BMP-2-induced human bone mesenchymal stem cells through mitochondrial dynamics and autophagy. Biomol Biomed. 2025 Mar 7;25(4):869-882.
[7] Hu Y, He X, Zang H, et al. Downregulation of Mfn2 Contributes to Chronic Postsurgical Pain via Inducing the Pyroptosis of GABAergic Neurons in the Spinal Cord. CNS Neurosci Ther. 2025 Jul;31(7):e70508.
[8] Wang D, Lv Y, Xie F, et al. An antioxidant, injectable hydrogel with mitochondrial fusion effect promotes inflamed dental pulp repair via immunomodulation and reactive oxygen species scavenging. Biomaterials. 2026 Jun;329:123985.
| Cell experiment [1]: | |
Cell lines | Human bone mesenchymal stem cells (BMSCs) |
Preparation Method | Human BMSCs were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The cells were transfected with a short hairpin-FoxO1 plasmid and treated with 1μM of MASM7, followed by culture in osteoblast differentiation-inducing medium containing 10ng/mL bone morphogenetic protein-2 (BMP-2) for 7 days. |
Reaction Conditions | 1μM; 7 days |
Applications | MASM7 significantly decreased cytoplasmic mitochondrial DNA level, decreased mitochondrial membrane potential level, increased adenosine triphosphate content, increased mitochondrial autophagy, increased microtubule-associated protein 1 light chain 3-II/I ratio, increased sequestosome-1, autophagy-related gene 5, autophagy-related gene 12, and damage-regulated autophagy modulator 1 protein levels, increased cell proliferation and migration, decreased cell apoptosis, increased extracellular matrix calcium deposition, upregulated forkhead box O-1, B-cell lymphoma-2, alkaline phosphatase, and runt-related transcription factor 2 protein expression levels, and downregulated Bcl-2-associated X protein and cleaved caspase-3 protein expression levels. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Rats were subjected to skin/muscle incision and retraction (SMIR) surgery to establish a chronic postsurgical pain model. MASM7 was administered via intrathecal injection. |
Dosage form | 10μg/10μL; intrathecal injection; once daily for seven consecutive days |
Applications | MASM7 alleviated SMIR-induced mechanical allodynia, improved mitochondrial function, reduced reactive oxygen species accumulation, and alleviated pyroptosis of gamma-aminobutyric acid-ergic neurons in the spinal cord. |
References: | |
| Cas No. | 920868-45-7 | SDF | |
| Formula | C22H23N5O2S2 | M.Wt | 453.58 |
| Solubility | DMSO : 100 mg/mL (220.47 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2047 mL | 11.0234 mL | 22.0468 mL |
| 5 mM | 440.9 μL | 2.2047 mL | 4.4094 mL |
| 10 mM | 220.5 μL | 1.1023 mL | 2.2047 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)